[{"orgOrder":0,"company":"Telomir Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Telomir-1","moa":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Telomir Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"","sponsorNew":"Telomir Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Telomir Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Telomir Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Telomir-1","moa":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Telomir Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Telomir Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Telomir Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Telomir Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Telomir-1","moa":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Telomir Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Telomir Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Telomir Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Telomir Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Telomir-1","moa":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Telomir Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Telomir Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Telomir Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Telomir Pharmaceuticals","sponsor":"Starwood Trust","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"","productType":"Small molecule","year":"2024","type":"Financing","leadProduct":"Telomir-1","moa":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Telomir Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Telomir Pharmaceuticals \/ Starwood Trust","highestDevelopmentStatusID":"4","companyTruncated":"Telomir Pharmaceuticals \/ Starwood Trust"},{"orgOrder":0,"company":"Telomir Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Telomir-1","moa":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Telomir Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Telomir Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Telomir Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Telomir Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Telomir-1","moa":"IL-17","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Telomir Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Telomir Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Telomir Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Telomir Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Telomir-1","moa":"IL-17","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Telomir Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Telomir Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Telomir Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Telomir Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Telomir-1","moa":"IL-17","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Telomir Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Telomir Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Telomir Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Telomir Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Telomir-1","moa":"IL-17","graph1":"Neurology","graph2":"Preclinical","graph3":"Telomir Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Telomir Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Telomir Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Telomir Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Telomir-1","moa":"IL-17","graph1":"Oncology","graph2":"Preclinical","graph3":"Telomir Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Telomir Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Telomir Pharmaceuticals \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Telomir Pharmaceuticals

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
filter

Year

filter

DEALS // DEV.

filter

Country

filter
Sponsor
filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

Therapeutic Area by Lead Product

ForexGraph

Study Phase by Lead Product

ForexGraph

Company by Lead Product

ForexGraph

Top Deals by Deal Size (USD bn)

ForexGraph

01

BePharma
Not Confirmed
BePharma
Not Confirmed

Details : Telomir-1 is the first novel small molecule, which suppresses cancer growth rather than promoting it and protects against chemotherapy-induced toxicity and mortality.

Product Name : Telomir-1

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

March 19, 2025

Lead Product(s) : Telomir-1

Therapeutic Area : Oncology

Highest Development Status : Preclinical

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

blank

02

BePharma
Not Confirmed
BePharma
Not Confirmed

Details : Telomir-1 is the first novel small molecule, which is proposed to be dosed orally, to lengthen the DNA’s protective telomere caps in order to potentially reverse age-related conditions.

Product Name : Telomir-1

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

February 26, 2025

Lead Product(s) : Telomir-1

Therapeutic Area : Neurology

Highest Development Status : Preclinical

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

blank

03

BePharma
Not Confirmed
BePharma
Not Confirmed

Details : Telomir-1 is the first novel small molecule, which is proposed to be dosed orally, to lengthen the DNA’s protective telomere caps in order to potentially reverse age-related conditions.

Product Name : Telomir-1

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

February 18, 2025

Lead Product(s) : Telomir-1

Therapeutic Area : Ophthalmology

Highest Development Status : Preclinical

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

blank

04

BePharma
Not Confirmed
BePharma
Not Confirmed

Details : Telomir-1 to fully reverse copper-induced elevation of reactive oxygen species (ROS) and provide robust cellular protection against copper toxicity in viral infections, such as avian influenza.

Product Name : Telomir-1

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

January 28, 2025

Lead Product(s) : Telomir-1

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Preclinical

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

blank

05

BePharma
Not Confirmed
BePharma
Not Confirmed

Details : Telomir-1 is the first novel small molecule, which is proposed to be dosed orally, to lengthen the DNA’s protective telomere caps in order to potentially reverse age-related conditions, like progeria.

Product Name : Telomir-1

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

January 07, 2025

Lead Product(s) : Telomir-1

Therapeutic Area : Genetic Disease

Highest Development Status : Preclinical

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

blank

06

BePharma
Not Confirmed
BePharma
Not Confirmed

Details : Telomir-1 is the first novel small molecule, which is proposed to be dosed orally, to lengthen the DNA’s protective telomere caps in order to potentially reverse age-related conditions.

Product Name : Undisclosed

Product Type : Small molecule

Upfront Cash : Not Applicable

December 23, 2024

Lead Product(s) : Telomir-1

Therapeutic Area : Genetic Disease

Highest Development Status : Preclinical

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

07

BePharma
Not Confirmed
BePharma
Not Confirmed

Details : The financing aims to advance the company's lead product Telomir-1. It is being evaluated for the treatment of osteoarthritis and Aging.

Product Name : Undisclosed

Product Type : Small molecule

Upfront Cash : Undisclosed

December 12, 2024

Lead Product(s) : Telomir-1

Therapeutic Area : Musculoskeletal

Highest Development Status : Preclinical

Sponsor : Starwood Trust

Deal Size : $1.0 million

Deal Type : Financing

blank

08

BePharma
Not Confirmed
BePharma
Not Confirmed

Details : Telomir-1 is the first novel small molecule, which is proposed to be dosed orally, to lengthen the DNA’s protective telomere caps in order to potentially reverse age-related conditions.

Product Name : Telomir-1

Product Type : Small molecule

Upfront Cash : Not Applicable

December 03, 2024

Lead Product(s) : Telomir-1

Therapeutic Area : Endocrinology

Highest Development Status : Preclinical

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

09

BePharma
Not Confirmed
BePharma
Not Confirmed

Details : Telomir-1 is the first novel small molecule, which is proposed to be dosed orally, to lengthen the DNA’s protective telomere caps in order to potentially reverse age-related conditions.

Product Name : Telomir-1

Product Type : Small molecule

Upfront Cash : Not Applicable

November 21, 2024

Lead Product(s) : Telomir-1

Therapeutic Area : Musculoskeletal

Highest Development Status : Preclinical

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

10

BePharma
Not Confirmed
BePharma
Not Confirmed

Details : Telomir-1 is the first novel small molecule, which is proposed to be dosed orally, to lengthen the DNA’s protective telomere caps in order to potentially reverse age-related conditions.

Product Name : Telomir-1

Product Type : Small molecule

Upfront Cash : Not Applicable

May 30, 2024

Lead Product(s) : Telomir-1

Therapeutic Area : Musculoskeletal

Highest Development Status : Preclinical

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank